Treatment of acute promyelocytic leukemia: A single institution experience. Tratamiento de la leucemia promielocítica aguda. Experiencia de una sola institución. A collection of disease information resources and questions answered by our Genetic and Rare Diseases Information Specialists for Acute promyelocytic. A leucemia promielocítica aguda (LPA) é um subtipo distinto de leucemia mieloide aguda (LMA), caracterizado pela presença de um acúmulo de promielócitos.

Author: Malasar Dijar
Country: Botswana
Language: English (Spanish)
Genre: Politics
Published (Last): 21 March 2017
Pages: 154
PDF File Size: 17.17 Mb
ePub File Size: 4.7 Mb
ISBN: 879-1-97131-835-2
Downloads: 3485
Price: Free* [*Free Regsitration Required]
Uploader: Tygor

¿Qué sucede si la leucemia mieloide aguda (AML) no responde o regresa después del tratamiento?

Toxicity and survival in de novo patients. Report of the first Latin American consensus conference for flow cytometric immunophenotyping of leukemia. Differentiation therapy of acute promyelocytic leukemia with tretinoin all-trans-retinoic acid. Am Soc Educ Program.

Treatment of acute promyelocytic leukemia with Arsenic compounds: Acute promyeloclocytic leukemia can promiepocitica coagulopathies which are frequently very serious due to hemorrhagic conditions. The molecular pathogenesis of acute promyelocytic leukaemia: Substantial progress has occurred in the treatment of APL because of improved understanding of the pathophysiology of the disease and identification of a molecular target.

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. J Am Stat Assoc ; Easy bruising or hemorrhagic diathesis epistaxis, gums bleeding, hematuria, petechiae, metroragia are frequently observed.


From genetics to treatment. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: New issues on pathogenesis and treatment response. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Mediterr J Hematol Infect Dis. Chromatin modulation by oncogenic transcription factors: Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia.

World Health Organization Classification of Leucemua Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.

Crit Rev Oncol Hematol.

Tratamiento de la leucemia promielocítica aguda: Experiencia de una sola institución

All-trans retinoic acid in the treatment of acute promyelocytic leukemia. Loss of the tumor suppressor PML in human cancer of multiple histologic origins. Normal levevel of antithrobin III in acute leukemia complicated by coagulopathy. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL?

Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: Targeting FLT3 for the treatment of leukemia.


Alterations of the FLT3 gene in acute promyelocytic leukemia: Results from several randomized studies have evaluated various regimens of ATRA alone or in combination with CT to determine optimal induction therapy in patients with newly diagnosed APL.

Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: Clin Lymphoma Myeloma Leuk, Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: Rearrangements of the retinoic acid receptor leucemai and promyelocytic leukemia zinc finger genes resulting from t 11;17 q23;q21 in a patient with acute promyelocytic leukemia.

Vasco de Quiroga No. Am Promielocitida Hematol ; High frequency of acute promyelocytic leukemia in Mexican mestizos. The according with results, the patients were classified following: Continuing high early death rate in acute promyelocytic leukemia: The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: Mechanisms of action of arsenic trioxide.

Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.